Welcome to our dedicated page for APOLLOMICS news (Ticker: APLMW), a resource for investors and traders seeking the latest updates and insights on APOLLOMICS stock.
Apollomics Inc. (APLMW, associated with Apollomics’ Nasdaq-listed shares under APLM) generates news that reflects its role as a clinical-stage biopharmaceutical company focused on oncology drug development. Company announcements frequently describe progress and challenges across its pipeline of oncology candidates, including vebreltinib (APL-101), an oral, highly selective c-Met inhibitor in a global Phase 2 multicohort trial for non-small cell lung cancer and other tumors with MET alterations.
Investors following Apollomics-related news can expect updates on clinical data, program prioritization and strategic decisions. The company has reported interim results from cohorts in its SPARTA trial, including activity in non-central nervous system MET fusion tumors and MET-amplified non-small cell lung cancer, as well as analyses in patients with MET exon 14 skipping mutations. News releases also cover outcomes from other programs, such as the Phase 3 bridging trial of uproleselan in China in relapsed or refractory acute myeloid leukemia, where the trial did not demonstrate favorable benefit and the program is being wrapped up.
Beyond clinical results, Apollomics’ news flow includes collaboration and licensing developments, such as its agreement with LaunXP for development and commercialization of vebreltinib in combination with an EGFR inhibitor in parts of Asia, and subsequent disclosures about payment disputes under that agreement. Financial updates, including annual and interim results, highlight research and development and administrative expenses, net losses and liquidity considerations.
Corporate governance and capital markets actions are also recurring themes. Recent items include reverse share split implementation, Nasdaq listing compliance updates, private placement (PIPE) financings, and changes in the board of directors and executive leadership. Some news has addressed operational continuity, describing earlier plans to seek shareholder approval to wind up the company and later communications indicating a reversal of those plans and continued development of vebreltinib. For readers tracking APLMW and APLM, this news stream provides context on Apollomics’ clinical, financial and corporate trajectory.
Apollomics Inc. (Nasdaq: APLM) announced a private placement financing of approximately $6 million through subscription agreements for a PIPE financing, with gross proceeds to fund pipeline programs and general corporate purposes. The financing involves the sale of 19,166,666 Class A ordinary shares at $0.30 per share, expected to close on May 8, 2024. Additionally, Dr. Robert Lin, M.D., Ph.D., an experienced physician and researcher, has been appointed to the board of directors, while Jonathan Wang, Ph.D., has resigned. Canaccord Genuity acts as the financial advisor for the financing.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.